TOMI Environmental Solutions Announces Additional CES Installation at a Pharmaceutical Facility in the UK

Rhea-AI Summary

TOMI Environmental Solutions (NASDAQ: TOMZ) has announced a new installation of its Custom Engineered Solution (CES) at a pharmaceutical facility in the United Kingdom. The facility is investing $500,000 in a twelve-applicator CES system that utilizes SteraMist iHP technology for efficient decontamination without requiring complete facility shutdowns.

The installation represents TOMI's strategic expansion in critical markets through its innovative technology offerings. The SteraMist technology uses Binary Ionization Technology (BIT) platform, which was developed under a defense grant with DARPA and employs low percentage hydrogen peroxide as its active ingredient to create ionized Hydrogen Peroxide (iHP) for superior disinfection.

Positive

• Secured $500,000 contract for CES system installation in UK pharmaceutical facility
• Expansion into international pharmaceutical market
• Technology enables continuous facility operations without shutdown requirements

Negative

• None.

Insights

Financial Analyst

The $500,000 CES system installation in a UK pharmaceutical facility represents significant revenue for TOMI Environmental Solutions, accounting for approximately 3% of their market cap. The deal highlights TOMI's ability to secure high-value contracts in the lucrative pharmaceutical sector, where stringent decontamination requirements create recurring revenue opportunities. The technology's ability to operate without facility shutdowns provides a compelling value proposition, potentially leading to increased adoption across the pharmaceutical industry. Looking at the broader market implications, TOMI's penetration into international markets and specifically the UK pharmaceutical sector positions them for potential growth in the European life sciences market. The custom nature of the installation also suggests higher margins compared to standard product sales.

Manufacturing Technology Expert

The twelve-applicator CES system represents a sophisticated technological implementation that addresses a critical pain point in pharmaceutical manufacturing - the need for continuous operations. The system's ability to perform decontamination without full facility shutdowns is a major competitive advantage in an industry where downtime can cost thousands per hour. The ionized Hydrogen Peroxide (iHP™) technology, developed through DARPA, offers superior disinfection while using lower chemical concentrations, making it both effective and environmentally conscious. This installation validates the scalability of TOMI's custom solutions and demonstrates their capability to handle complex enterprise-level implementations. The pharmaceutical industry's adoption of this technology could set new standards for clean room and manufacturing facility decontamination protocols.

FREDERICK, Md., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announced today another installation of the Custom Engineered Solution (CES) at a renowned pharmaceutical facility in the United Kingdom.

This pharmaceutical facility is expanding its decontamination capabilities with a $500,000 investment in a new twelve-applicator CES system. By leveraging TOMI’s highly effective SteraMist iHP technology, the company ensures efficient and rapid decontamination without full facility shutdowns, eliminating interruptions and maintaining continuous operations. This milestone underscores TOMI’s strategy to expand its presence in critical markets through superior technology and innovative, customized equipment offerings worldwide.

Dr. Halden Shane, CEO of TOMI Environmental Solutions, commented, “This installation demonstrates the increased demand for our SteraMist technology by life science industry leaders. We look forward to showcasing our latest upgraded CES system, robust technical team, and streamlined operations during the design and installation of this international custom system.”

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.

For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products to serve education sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com

FAQ

What is the value of TOMI's (TOMZ) new CES installation contract in the UK?

The UK pharmaceutical facility is investing $500,000 in TOMI's new twelve-applicator CES system.

How does TOMI's (TOMZ) SteraMist technology benefit pharmaceutical facilities?

SteraMist technology enables efficient and rapid decontamination without requiring full facility shutdowns, allowing continuous operations.

What technology does TOMI (TOMZ) use in its decontamination systems?

TOMI uses Binary Ionization Technology (BIT) platform, which employs low percentage hydrogen peroxide to create ionized Hydrogen Peroxide (iHP) for disinfection.

Where was TOMI's (TOMZ) Binary Ionization Technology developed?

The technology was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense.